Lombard Medical Technologies announced that Lombard Medical has filed a registration statement on Form F-1 with the US Securities and Exchange Commission (SEC) relating to a proposed initial public offering of its ordinary shares. The number of shares to be offered and the price range for the offering have not yet been determined.
The company has reserved the ticker “EVAR” for its listing on the NASDAQ Global Market. In connection with the NASDAQ listing, Lombard Medical will also delist its ordinary shares from AIM, a market of the London Stock Exchange and complete a change of domicile, with Lombard Medical, a Cayman Islands corporation, becoming the holding company for the group.
According to a company release, Lombard Medical intends to use proceeds from the proposed NASDAQ offering to expand its direct sales force in the United States and develop new products to treat complex vascular disease, including a stent graft to treat aneurysms in the thoracic aorta. The remaining proceeds will be used for working capital and for general corporate purposes.
Jefferies LLC and Barclays Capital Inc are acting as joint book-running managers or the proposed offering, and BTIG, LLC is acting as co-manager.
A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.
